About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study
Rajesh Kumar Singh, Sangeeta Pankaj, Vamsi Raj Kota, Sumit Kumar
Department of Radiation Oncology, Regional Cancer Centre, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar, India.
Corresponding Author:
Dr. Rajesh Kumar Singh
Email: drprashanthp@gmail.com
Received: 13-OCT-2014 Accepted: 14-JAN-2015 Published Online: 28-FEB-2015
DOI: http://dx.doi.org/10.17659/01.2015.0024
Abstract
Introduction: Nab-paclitaxel is a novel cremophor free nanoparticle of albumin-stabilized paclitaxel.  We evaluated the efficacy and toxicity of the nab-paclitaxel in recurrent ovarian cancer patients. Methods: 17 patients of recurrent epithelial ovarian cancer with platinum and taxane resistance defined by persistent or progressive disease following recurrence within six months of treatment completion and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or elevated CA-125 (= 70 U/mL) in patients without measurable disease were included in trial. Patients were treated with nab-paclitaxel for six cycles or until disease progression. Results: Median age of patients was 62 years; 76% of patients had stage IIIC or IV disease, 82% had Eastern Cooperative Oncology Group performance status of 0, and 88% had prior surgery. For assessable patients, the objective response rate (ORR) was 58% (6 complete responses [CR] and 4 partial responses [PR] among 17 assessable patients). In patients evaluated with RECIST only, the ORR was 44.4% (one CR and three PR of 9 patients). In patients with only elevated CA-125, ORR was 75% (5 CRs and 1 PRs of 8 patients). Median time to response was 1.3 months (range 0.5 to 4.8 months). Estimated median progression-free survival was 8.5 months. The most frequent grade 3 to 4 treatment-related toxicities were neutropenia (35%) and neuropathy (11%). Conclusion: Nab-paclitaxel as a single agent in patients with recurrent epithelial ovarian cancer seems to be well tolerated and effective in patients who are previously treated with paclitaxel or platins.
Keywords : Paclitaxel, Epithelial Neoplasms, Neutropenia, Disease-Free Survival, Taxoids, Humans.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share